PPARG and scleroderma: Moreover, treatment with synthetic PPAR-γ ligands was shown to attenuate experimentally-induced hepatic [18], cardiac [19] and kidney [20] fibrosis, and prevent bleomycin-induced scleroderma [21], in vivo.